PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14723561-4	2004	The same dosage of cetuximab combined with irinotecan, fluorouracil and folinic acid (various regimens) produced partial responses in 43-58% of patients, a complete response in 5% of patients (one study only) and stable disease in 32-52% of patients with treatment-naive metastatic colorectal cancer expressing EGFR in three small, open-label trials.	Leucovorin	72-84	epidermal growth factor receptor	Homo sapiens	311-315	
16303861-0	2006	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.	Leucovorin	40-52	epidermal growth factor receptor	Homo sapiens	121-153	
22192364-3	2012	Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS.	Leucovorin	69-79	epidermal growth factor receptor	Homo sapiens	5-9	
22192364-3	2012	Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS.	Leucovorin	81-93	epidermal growth factor receptor	Homo sapiens	5-9	
22192364-3	2012	Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS.	Leucovorin	135-145	epidermal growth factor receptor	Homo sapiens	5-9	
22192364-3	2012	Anti-EGFR agents can be added to first-line FOLFIRI (5-fluorouracil, leucovorin [folinic acid], irinotecan) or FOLFOX (5-fluorouracil, leucovorin [folinic acid], oxaliplatin) in patients whose tumors express wild-type KRAS.	Leucovorin	147-159	epidermal growth factor receptor	Homo sapiens	5-9	
16794239-3	2006	DESIGN: This review summarizes current clinical data for EGFR-TKIs as monotherapy or in combination with 5-fluorouracil/leucovorin, irinotecan, or oxaliplatin, focusing on the rapidly developing area of colorectal, gastroesophageal, and pancreatic cancers.	Leucovorin	120-130	epidermal growth factor receptor	Homo sapiens	57-61	
28084171-23	2017	Oral followed by intravenous folinic acid may be used in patients with staggered ingestion >36 h or patients with acute overdose and renal impairment (eGFR <45 mL/min/1.73 m2).	Leucovorin	29-41	epidermal growth factor receptor	Homo sapiens	154-158	
27091477-0	2016	Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.	Leucovorin	62-72	epidermal growth factor receptor	Homo sapiens	0-32